Dr. Daniels Discusses the Findings of the 2007-2012 PROCLAIM National Registry

Gregory A. Daniels, MD, PhD
Published: Thursday, Aug 07, 2014

Gregory A. Daniels, MD, PhD, Associate Clinical Professor of Medicine, Division of Hematology-Oncology, University of California, San Diego, discusses the findings of the 2007-2012 PROCLAIM national registry, which collected retrospective data from 170 patients with metastatic melanoma who received at least one dose of HD IL-2.

IL-2 can elicit responses in patients with metastatic melanoma that last years. Daniels says this database looked back 5 years and found that IL-2 continues to deliver the same durability.

The registry also found that selecting patients for this therapy is important. Daniels says normal LDH and patient performance status can predict how well the patient will do on the treatment.

However, patients with stable disease or those who did not initially respond to treatment with IL-2 had better overall survival than previously thought, according to the registry findings.

Gregory A. Daniels, MD, PhD, Associate Clinical Professor of Medicine, Division of Hematology-Oncology, University of California, San Diego, discusses the findings of the 2007-2012 PROCLAIM national registry, which collected retrospective data from 170 patients with metastatic melanoma who received at least one dose of HD IL-2.

IL-2 can elicit responses in patients with metastatic melanoma that last years. Daniels says this database looked back 5 years and found that IL-2 continues to deliver the same durability.

The registry also found that selecting patients for this therapy is important. Daniels says normal LDH and patient performance status can predict how well the patient will do on the treatment.

However, patients with stable disease or those who did not initially respond to treatment with IL-2 had better overall survival than previously thought, according to the registry findings.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Evolving Roles for Targeted Melanoma Therapies: Assessing Rapid Progress in the Field and Looking Toward Future CombinationsFeb 28, 20191.5
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Publication Bottom Border
Border Publication
x